Immunotherapy Focus Takis specializes in cancer immunotherapy by instructing the immune system to recognize and reject tumors, presenting opportunities to partner on allele- or biomarker-guided immuno-oncology programs, personalized therapeutic strategies, and companion diagnostic development.

In Vivo Gene Delivery Core capability in delivering genes in vivo via gene-electro-transfer with over a decade of experience, offering collaboration for gene therapy constructs, delivery optimization, and translational studies in tumor tissue or skeletal muscle to enhance therapeutic efficacy.

Biomarker & Diagnostics Active work identification of new biomarkers and development of molecular diagnostic tests, signaling potential for co-development deals, assay validation partnerships, and companion diagnostic opportunities to enable patient stratification.

Partnership Advantage Market positioning as an efficient, fast, low-cost research partner with strong academic and industrial collaborations, suitable for outsourcing early-stage studies, preclinical feasibility, and rapid iteration in drug and diagnostic research.

Financial Profile Revenue in the range of tens of millions and a focused team size, indicating a scalable partner for mid-stage collaborations, licensing discussions, or joint ventures with potential for volume-driven revenue growth as programs advance.